Listening to Your Compliance Challenges. Delivering Creative Solutions.

Edge production facilities are fully operational. Call us or register online.

Create an Account

Exceeding expectations one customer at a time

Edge Pharma is an FDA registered 503B Outsourcing Facility offering high quality innovative solutions for the healthcare community. The world-class scientific, pharmacy, and engineering staff at Edge Pharma understands the challenges healthcare organizations, whether large or small, are tackling. As your compliance partner, we are dedicated to providing turnkey 503B outsourcing with the highest level of quality, easy ordering, simple logistics, and excellent customer support.

Contact Us

856 Hercules Drive,
Colchester, VT 05446

Phone: 802-992-1178
Fax: 802-489-6300

Contact Us

Careers at Edge

We are growing and looking for talented people.

Visit Careers Page



Edge Product Highlight

  • MVASITM Bevacizumab: Edge Pharma offers repackaged MVASI™ (bevacizumab-awwb) in unit-dose silicone free syringes. No vial drop-shipping means both device compliance and convenience.
  • LET Gel: Unit-dose syringes of compounded LET Gel for hospital emergency departments, urgent care centers, pediatrician offices, and other qualified health care providers. LET Gel is a topical anesthetic consisting of Lidocaine, Epinephrine, and Tetracaine.
  • Gemcitabine Bladder Instillation Kitcompounded Gemcitabine Bladder Instillation Syringe kits with a 1g / 50mL pre-filled unit-dose syringe of Gemcitabine, a closed system transfer device (CSTD), and catheter tip.
  • Methacholine Challenge Test Kit: Prefilled, color coded, and barcoded unit dose syringes are simple and convenient to use.


 

eyelid skin cancer post 225

Let Gel and Eyelid Skin Cancer

Ultraviolet light is damaging not only to the eyes, but to the “thinnest and most sensitive skin on the body,” – the eyelid. Between 5 and 10% of all skin cancers are found on the eyelid. Approximately 90% of eyelid skin cancers are basal cell carcinomas...   [continue]

 

Vancomycin and C diff prevention 225

Oral Vancomycin and Prevention of C. diff

A recent study at a North Carolina hospital investigated whether oral vancomycin, given prophylactically, would prevent healthcare facility-onset Clostridiodes difficile infection in patients at high risk...   [continue]

 

women urology 225

Urology Care Foundation Focuses Attention on Women’s Urological Health

May is Women’s Health Month and the Urology Care Foundation, the world’s leading nonprofit urological health foundation, is working to raise awareness of urological conditions that mostly affect women, such as overactive bladder, urinary tract infections, and interstitial cystitis...   [continue]

 

LET Gel in Urban Hospital 225

LET Gel Initiative Effective in Urban Hospital

A recent initiative to help a large urban pediatric emergency department handle the pain of lacerations had success that was both measurable and sustainable ...   [continue]

Read More News ...